Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to “Sell”

Wall Street Zen downgraded shares of Gyre Therapeutics (NASDAQ:GYRE) from a hold rating to a sell rating in a research report released on Saturday morning.

A number of other equities analysts have also commented on GYRE. Weiss Ratings lowered Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Zacks Research downgraded Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $17.00.

Gyre Therapeutics Price Performance

Gyre Therapeutics stock opened at $6.55 on Friday. The stock’s fifty day moving average price is $7.43 and its two-hundred day moving average price is $7.65. Gyre Therapeutics has a one year low of $6.55 and a one year high of $11.67. The firm has a market cap of $635.55 million, a PE ratio of -72.77 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The company had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million. Sell-side analysts expect that Gyre Therapeutics will post -0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at Gyre Therapeutics

In related news, CEO Ying Luo sold 10,136 shares of the firm’s stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $8.04, for a total transaction of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares of the company’s stock, valued at $20,624,417.04. This trade represents a 0.39% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 10.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of GYRE. State of Alaska Department of Revenue bought a new stake in shares of Gyre Therapeutics during the third quarter worth about $38,000. Bank of America Corp DE grew its holdings in shares of Gyre Therapeutics by 28.8% during the second quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock worth $46,000 after purchasing an additional 1,402 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Gyre Therapeutics during the fourth quarter worth about $77,000. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.